Takeda Pharmaceutical Company Limited

http://www.takeda.com

03.06.2018 – 14:31
Takeda Highlights Favorable Safety Profile of Entyvio® (vedolizumab) Through Comparative Real-World Data Versus TNFalpha-Antagonist Therapy in Ulcerative Colitis and Crohn's Disease
Osaka, Japan (ots/PRNewswire) - Takeda demonstrates leadership in GI by featuring new U.S. VICTORY Consortium data among its 24 sponsored Entyvio abstracts presented at the Digestive Disease Week (DDW) 2018 meeting Takeda Pharmaceutical Company Limited (TSE: 4502) ("Takeda") today announced a new analysis of ...
mehr
16.02.2018 – 17:01
Entyvio® (vedolizumab) Shows Higher Rates of Mucosal Healing Versus TNFalpha-Antagonist Therapy in Ulcerative Colitis and Crohn's Disease Patients in Comparative Effectiveness Real-World Data Analysis
Osaka, Japan (ots/PRNewswire) - New clinical study also provides data for Entyvio® in inducing complete mucosal healing and endoscopic remission, particularly in bio-naïve patients Takeda Pharmaceutical Company Limited (TSE: 4502) ("Takeda") today announced new real-world data evaluating the comparative ...
mehr
01.11.2017 – 09:32
Meta-Analysis Using Real-World Data Evaluates Safety Profile of Entyvio® (vedolizumab) in Patients with Moderate to Severe Ulcerative Colitis or Crohn's Disease
Osaka, Japan (ots/PRNewswire) - New meta-analysis provides a comprehensive view of real-world data and furthers understanding of Entyvio as an important treatment option for patients with ulcerative colitis or Crohn's disease Takeda Pharmaceutical Company Limited (TSE: 4502) ("Takeda") today announced the ...
mehr
30.03.2017 – 09:02
Takeda Announces Appointment of New President of Europe and Canada Business Unit
Zurich (ots/PRNewswire) - Takeda Pharmaceutical Company Limited ("Takeda") announced today that Giles Platford will assume the role of President of the Europe and Canada (EUCAN) Business Unit of Takeda. In this role he will lead business operations in the region effective April 1, 2017. Giles Platford, who joined Takeda in 2009, is also a Corporate Officer and member ...
mehr
13.07.2016 – 08:01
IBD Unmasked, a First-of-its-Kind Global Awareness Initiative, Launches to Support and Empower the Inflammatory Bowel Disease Community
Osaka, Japan (ots/PRNewswire) - Takeda unveils new IBD Super Hero and graphic illustrations, developed in collaboration with Marvel Custom Solutions, to highlight the strength of and inspire confidence in those living with IBD If someone with inflammatory bowel disease (IBD) was a Super Hero, what would that hero ...
mehr
27.05.2014 – 14:17
Takeda Receives European Commission Marketing Authorisation for Entyvio® (vedolizumab) for the Treatment of Ulcerative Colitis and Crohn's Disease
Zurich And Osaka, Japan (ots/PRNewswire) - Discovery Minerals (DSCR) Undervalued and Nearing Its SqueezeTrigger Price According to WealthMakers.com Report May 27, 2014 WEALTHMAKERS.COM / www.wealthmakers.com [http://www.wealthmakers.com ] , a Wall Street research and trading firm providing unbiased statistical stock ...
mehr
24.09.2013 – 08:01
Takeda Receives Simultaneous European Marketing Authorization for Three New Type 2 Diabetes Therapies, Vipidia[TM] ? (alogliptin) and Fixed-Dose Combinations Vipdomet[TM] ? (alogliptin and metformin) and Incresync[TM] ? (alogliptin and pioglitazone)
Osaka, Japan (ots/PRNewswire) - Takeda Pharmaceutical Company Limited (Takeda) today announced that the European Commission has granted Marketing Authorization (MA) for Vipidia[TM] (alogliptin), a dipeptidyl peptidase IV (DPP-4) inhibitor, for the treatment of type 2 diabetes patients who are uncontrolled on ...
mehr
22.10.2012 – 08:03
More Than 15 Years Experience: Takeda Marks one Billion Treatment Courses of Gastric Ulcer Drug Pantoprazole
Zurich (ots/PRNewswire) - ? Takeda Pharmaceuticals International GmbH ("Takeda") today announced that over one billion treatment courses of its gastrointestinal product pantoprazole have been administered around the world.[1] Initially launched in 1994 in Germany, pantoprazole, a proton pump inhibitor (PPI) used to ...
mehr
04.09.2012 – 13:02
Revestive(R) (Teduglutide) Receives European Marketing Authorization for the Treatment of Adults With Short Bowel Syndrome (SBS)
Osaka, Japan And Bedminster, New Jersey (ots/PRNewswire) - - SBS is a rare and highly disabling condition that impacts patients' quality of life and can lead to serious life-threatening complications. - Teduglutide has received orphan drug designation for the treatment of SBS from the European Medicines Agency (EMA) ...
mehr

22.06.2012 – 14:21
Takeda Receives Positive CHMP Opinion for Teduglutide (Revestive®) for Patients with Short Bowel Syndrome
Osaka, Japan And Bedminster, New Jersey (ots/PRNewswire) - - European CHMP adopts positive opinion for teduglutide (Revestive(R)) for patients with short bowel syndrome (SBS) - SBS is a rare and highly disabling condition that impacts patients' quality of life and can lead to serious life-threatening complications - ...
mehr
25.05.2012 – 10:22
Takeda to Acquire Multilab, Enhancing its Business Infrastructure in Brazil
Osaka, Japan, And São Jerônimo, Brazil (ots/PRNewswire) - ? Takeda Pharmaceutical Company Limited (Osaka, Japan, "Takeda") and Multilab Industria e Comercio de Produtos Farmaceuticos Ltda. (Rio Grande do Sul, Brazil, "Multilab") today jointly announced that both parties have signed an agreement whereby Takeda Farmaceutica Brasil Ltda. (Sao Paulo, Brazil, "Takeda ...
mehr
27.02.2012 – 09:03
Takeda Announces Acceptance of European Marketing Authorisation Application for Peginesatide, an Investigational Compound for the Treatment of Anemia Associated with Chronic Kidney Disease in Patients on Dialysis
London And Osaka, Japan (ots/PRNewswire) - Takeda Pharmaceutical Company Limited (Takeda) today announced that Takeda Global Research & Development Centre (Europe) Ltd received confirmation of acceptance for assessment from the European Medicines Agency (EMA) for a Marketing Authorisation Application (MAA) for the ...
mehr
18.01.2012 – 10:03
Takeda Announces Strategic Measures to Achieve Efficiencies for Long-Term Growth
Osaka, Japan (ots/PRNewswire) - Takeda Pharmaceutical Company Limited announced today strategic measures to better align its global workforce and consolidate site operations in order to integrate legacy Nycomed operations, strengthen its presence in more than 70 countries, adapt to changing market conditions and maintain a focus on growth through innovation and ...
mehr
08.12.2011 – 16:23
Takeda's Edarbi® (azilsartan medoxomil) Receives European Marketing Authorisation for the Treatment of Essential Hypertension
London and Osaka, Japan (ots/PRNewswire) - Takeda Pharmaceutical Company Limited (Takeda) today announced that the European Commission has granted marketing authorisation for Edarbi(R) (azilsartan medoxomil), a new once-daily angiotensin receptor blocker (ARB) (also known as angiotensin II receptor antagonist ...
mehr
30.09.2011 – 13:02
Takeda Completes Acquisition and Names New CEO of Nycomed
Osaka, Japan (ots/PRNewswire) - Takeda Pharmaceutical Company Limited announced it has completed its acquisition of Nycomed A/S ("Nycomed") for 9.6 billion Euro on a cash-free, debt-free basis and made Nycomed a wholly owned subsidiary of Takeda effective the same day. Dr. Frank Morich has been named CEO of Nycomed in addition to his current role as Executive Vice President (EVP), International Operations ...
mehr
23.09.2011 – 14:29
Takeda Receives Positive CHMP Opinion in Europe for Edarbi(TM) (azilsartan medoxomil) for the Treatment of Essential Hypertension
London and Osaka, Japan (ots/PRNewswire) - Takeda Pharmaceutical Company Limited (Takeda) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion for EdarbiTM (azilsartan medoxomil, development code: TAK-491), a new ...
mehr
20.10.2010 – 09:06
Takeda Submits European Marketing Authorisation Application for Azilsartan Medoxomil, an Investigational Compound for the Treatment of Essential Hypertension
London and Osaka, Japan (ots/PRNewswire) - Takeda Pharmaceutical Company Limited (Takeda) today announced that Takeda Global Research & Development Centre (Europe), Ltd. submitted a Marketing Authorisation Application (MAA) for azilsartan medoxomil (development code: TAK-491), an angiotensin II receptor ...
mehr
15.07.2010 – 01:07
Takeda Responds to FDA Advisory Committee Recommendation
London, July 15, 2010 (ots/PRNewswire) - The U.S. Food and Drug Administration (FDA) Endocrinologic and Metabolic Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee held a joint meeting primarily focused on reviewing the cardiovascular (CV) safety of rosiglitazone, as presented by the FDA and GlaxoSmithKline. Following this two day discussion, Takeda Pharmaceuticals North America, Inc. ...
mehr

01.02.2010 – 14:58
First Treatment to Improve Survival in 20 Years
Osaka, Japan and London (ots/PRNewswire) - Takeda Pharmaceutical Company Limited ("Takeda") and Takeda Pharmaceuticals Europe Limited ("TPEU"), its wholly owned subsidiary for oversight of pan-European sales and marketing, jointly announced today that Mepact(R) (mifamurtide)(1), the first new treatment in 20 years to improve survival in patients with osteosarcoma (malignant bone cancer)(2), is now commercially ...
mehr
01.10.2009 – 10:40
Takeda to Establish Four Sales and Marketing Subsidiaries to Expand its Operations in Mexico, Turkey and Five Other Countries in Europe
Osaka, Japan (ots/PRNewswire) - Takeda Pharmaceutical Company Limited (Osaka, Japan, "Takeda") announced today it will establish four new commercial subsidiaries covering Mexico, Turkey, Sweden, Norway, Denmark, Belgium and Luxembourg. The new subsidiaries - Takeda Pharmaceuticals Mexico, S.A. de C.V., Takeda ...
mehr
31.03.2008 – 19:16
New Data Showed ACTOS(R) (pioglitazone HCl) Prevented Progression of Atherosclerotic Plaque Volume in Patients With Type 2 Diabetes
Chicago (ots/PRNewswire) - - Data Expands Body of Evidence in High Risk Population Using IVUS, a Unique Marker for Coronary Atherosclerosis New data from a clinical trial using intravascular ultrasound (IVUS) technology found that in patients living with type 2 diabetes, ACTOS(R) (pioglitazone HCl) ...
mehr
19.09.2007 – 14:16
New Research Shows ACTOS(R) (pioglitazone HCI) is Associated With a 38% Lower Risk of Heart Attack in Type 2 Diabetes
Amsterdam (ots/PRNewswire) - - For Non-US Media Only New research, including two studies presented this week at the 43rd Annual Meeting of the European Association for the Study of Diabetes (EASD), further support the cardiovascular safety of ACTOS(R) (pioglitazone HCI) and its benefits regarding improved ...
mehr
31.07.2007 – 03:32
Takeda Responds to the FDA Advisory Committee Recommendation
London (ots/PRNewswire) - Following a joint meeting today of the U.S. Food and Drug Administration (FDA) Endocrinologic and Metabolic Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee, Takeda Global Research & Development (TGRD) underscores its position that ACTOS(R) (pioglitazone HCl) offers a proven safety profile regarding the risk of cardiovascular disease. "The breadth ...
mehr